114 results about "Polysorbate 80" patented technology

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

The invention provides an anti-freezing denaturation agent for golden and tiger hybrid spotted fish meat protein and a preparation method of the anti-freezing denaturation agent. The invention relates to an anti-freezing denaturation agent for protein of Jinhu hybrid spotted fish. The anti-freezing denaturation agent is prepared from the following raw materials in parts by weight: 5 to 8 parts of trehalose-mannitol, 0.5 to 1 part of nano chitosan, 0.2 to 0.5 part of rosmarinic acid and 0.1 to 0.2 part of polysorbate-80. The trehalose-mannitol is prepared from trehalose and mannitol. Aiming at the characteristics of Jinhu hybrid spotted fish meat, trehalose-mannitol, nano chitosan, rosmarinic acid and polysorbate-80 are taken as raw materials and compounded to obtain a new formula of the protein anti-freezing denaturation agent for the Jinhu hybrid spotted fish meat, and the anti-freezing denaturation agent prepared by adopting the formula and the process disclosed by the invention can be used for inhibiting protein degradation and improving the anti-freezing denaturation effect of the Jinhu hybrid spotted fish meat. The decrease range of MP protein concentration, MP total sulfydryl content and MP Ca < 2 + >-ATPase activity of the antifreeze agent is obviously reduced, and the effect of the antifreeze agent is superior to that of a commercially available antifreeze agent. Moreover, the anti-freezing denaturation agent for the protein of the Jinhu hybrid spotted fish does not contain phosphorus, and has the advantages of safety and high efficiency.

The invention provides a docetaxel-loaded platelet delivery system as well as a preparation method and application thereof, and relates to the technical field of medicines. According to the invention, the docetaxel-loaded platelet delivery system is obtained by loading the docetaxel with the platelets for the first time, so that the problem that in the prior art, the traditional docetaxel preparation (injection) needs to be solubilized by polysorbate 80, so that allergy is easily caused is avoided, the safety and biocompatibility of the docetaxel medicine are improved, and the docetaxel-loaded platelet delivery system is suitable for clinical application. And the docetaxel-loaded platelet delivery system has excellent stability and can be stored at normal temperature for a long time. The invention provides the preparation method of the docetaxel-loaded platelet delivery system, and the method is simple to operate, high in encapsulation efficiency and drug loading rate and suitable for popularization. The docetaxel-loaded platelet delivery system disclosed by the invention has an outstanding treatment effect on melanoma and has a good application prospect.

Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.

The invention relates to the technical field of biological pharmacy, and discloses a preparation method of a ready-to-use stable 3D-MLA adjuvant solution, which comprises the following steps: dissolving citric acid monohydrate and trisodium citrate dihydrate in water for injection to prepare a citrate buffer solution; adding polysorbate 80 into the citrate buffer solution while stirring, and dissolving the polysorbate 80; adding 3D-MLA into the obtained solution under stirring, and dissolving the 3D-MLA; adjusting the pH value of the solution; fixing the volume by using water for injection; sterilizing and filtering through a filter membrane, filling a container with filtrate, and sealing; and refrigerating and storing. According to the present invention, the citrate buffer solution is adopted, the pH value of the adjuvant solution is adjusted, and the combination effect of the buffer system and the pH environment is utilized, such that the chemical degradation of the 3D-MLA in the injection water is effectively inhibited, the technical problem that the solution is easily degraded is solved, and the ready-to-use preparation capable of maintaining the stability under the refrigeration storage condition is obtained.

The application relates to the technical field of cough-relieving medicines, and discloses a high-efficiency cough-relieving loquat particle composition which is composed of the following components in parts by weight: loquat leaf extract 30-40 parts; white front extract 10-15 parts; platycodon grandiflorum extract 6-10 parts; white mulberry bark extract 18-25 parts; stemona sessiliflora extract 7-10 parts; menthol 0.1-0.5 part; polyethylene glycol 2-5 parts; mannitol 8-12 parts; ethyl cellulose 3-6 parts; hydroxypropyl methyl cellulose 1-3 parts; phosphatidylcholine 1-3 parts; polysorbate 80 1-3 parts; cross-linked sodium carboxymethyl cellulose 4-6 parts; and sucrose 40-60 parts. The double dispersion system combining the immediate-release component and the sustained-release component is adopted, the solubility and the initial release speed of the traditional Chinese medicine extract are remarkably improved through the addition of polyethylene glycol and mannitol, and the technical effect that the drug effect appearing time is remarkably shortened is achieved. Compared with the technical scheme relying on only a single release mode in the prior art, the deficiency that the drug effect is slow and the symptoms of the patient cannot be timely relieved is solved.

The application discloses a kind of bumetanide tablets, raw materials include bumetanide 1 according to mass ratio;Corn starch 81~85;Lactose 50~54;Agar 0.1~0.3;Povidone K304~6;Polysorbate 80, 0.1~0.2;Silicon dioxide 3~4.5;Talcum powder 2~3.3;Magnesium stearate 0.3~0.7.Its preparation method includes the following steps: pretreatment, premixing, granulation, wet granulation, drying, dry granulation, total mixing, tabletting and packaging.The application introduces the synergistic system of trace agar and polysorbate 80 in the prescription.Agar, as a natural hydrophilic colloid, can form a hydrophilic network structure during the granulation process, and synergistically act with polysorbate 80, greatly improving the wettability and dispersibility of the slurry to ultrafine bumetanide, preventing drug agglomeration, so that the drug can be more evenly distributed in the granules during the subsequent drying and tabletting process.

The invention discloses an oyster enzymolysis ultrafiltration extract nasal spray and a preparation method thereof, the nasal spray comprises the following components: 5-10 wt% of oyster extract, 0.1-0.3 wt% of preservative, 0.05-0.15 wt% of sodium chloride and 0.1-0.3 wt% of emulsifier, the pH value is 5.5-6.5, the content of the preservative is 0.1-0.3 wt%, the content of the sodium chloride is 0.05-0.15 wt%, the content of the emulsifier is 0.1-0.3 wt%, and the balance is water. The preservative is one of benzalkonium chloride, sorbic acid and potassium sorbate, and the emulsifier is polysorbate 80. Through definite raw material composition, a step-by-step process and quality control, the bioavailability of active components is improved, the flavor of the product is optimized, the effect of safely and efficiently improving sleep is achieved, the problems of low bioavailability, poor flavor and potential safety hazards of an existing sleep improving product are solved, the process repeatability is high, and the preparation method is suitable for industrial production. The long-term use of people with chronic insomnia is facilitated.

The invention relates to a pharmaceutical composition, which is prepared from adapalene, benzoyl peroxide, a traditional Chinese medicine extract, an acrylamide and acryloyl dimethyl sodium taurate copolymer, a mixture of isohexadecane and polysorbate 80, docusate sodium, EDTA (Ethylene Diamine Tetraacetic Acid) disodium, glycerol, poloxamer 124, propylene glycol and water, the traditional Chinese medicine extract comprises moutan bark, salvia miltiorrhiza, radix rehmanniae recen, radix sophorae flavescentis, coptis chinensis, rheum officinale, scutellaria baicalensis, menthol and borneol. According to the pharmaceutical composition disclosed by the invention, the synergistic antibacterial and anti-keratosis curative effects of adapalene and benzoyl peroxide can be maintained, and meanwhile, the occurrence rate of local skin dryness, erythema, desquamation, burning heat sensation and contact dermatitis can be remarkably reduced.

The present application relates to string maintenance nanoemulsion and its preparation method, belong to string maintenance technical field. The nanoemulsion includes: polysorbate 80, stearic acid sorbitan 60 as main emulsifier, glycerin monostearate, cetyl alcohol, stearyl alcohol as auxiliary emulsifier, liquid paraffin, xanthan gum adjusts consistency, chitosan carries sodium hyaluronate nanoparticle as long-acting moisturizing agent, glycerol, propylene glycol is humectant and can be used as antifreezing agent; hydroxyphenyl ethyl as preservative; can also selectively add essence, the balance is water. The water-soluble ingredients are mixed and stirred uniformly; the oil-soluble ingredients are mixed and stirred uniformly; the oil phase is added to the water phase, and the primary emulsion is stirred and emulsified, and the essence is added after cooling, and the present application is obtained. The present application realizes long-acting moisturizing and nourishing of the string by introducing chitosan carrying sodium hyaluronate nanoparticles, and has the advantages of fine texture, softness and the like.

The invention discloses a method for detecting polysorbate 80 based on an MALDI-MS and UHPLC-Q-TOF / MS. The method comprises the following steps: taking a polysorbate 80 sample, preparing a polysorbate 80 solution by using acetonitrile, respectively carrying out MALDI-MS detection and UHPLC-Q-TOF / MS detection on the polysorbate 80 solution, and determining the content of the polysorbate 80 in the polysorbate 80 sample according to the MALDI-MS and UHPLC-Q-TOF / MS detection results. The method comprises the following steps: acquiring PS80 principal component distribution according to an MALDI-MS (Matrix-Assisted Laser Desorption Ionization-Mass Spectrometry) map: a polyoxyethylene chain delta m / z 44.0 + / -0.2 and an esterified derivative sodium adduct ion gradient peak cluster, and carrying out qualitative analysis on components of the polysorbate 80 in combination with a characteristic interval of m / z 44.0 + / -0.2 in the MALDI map; according to the retention time in the UHPLC-Q-TOF / MS detection result, identifying the monoester, diester and trace unesterified sorbitan in the polysorbate 80. According to the invention, molecular weight distribution analysis and component separation and identification of PS80 are realized.

A noninvasive ophthalmic formulation, comprising a chelator (such as EDTA and its salts), a transport enhancer (such as Methyl Sulfonyl Methane; MSM), a second polyoxyalkylene permeation enhancer such as propylene glycol capable of enhancing permeation through lipid-thickened ocular membranes, a thickening agent such as hydroxyethyl cellulose (HEC) and a surfactant such as polysorbate 80, is provided. The novel combination of the ingredients unexpectedly and beneficially reduces symptoms associated with early-stage, age-related cataracts. Methods for treating cataracts with compositions of the invention and measurement of improved visual function by measuring contrast sensitivity (CS) are provided.

The application discloses a virus-like particle vaccine freeze-drying protective agent and a preparation method thereof. The freeze-drying protective agent comprises A liquid and B liquid mixed in a volume ratio of 1:1 to 3:1; the A liquid comprises the following components with terminal concentrations: 0.01-0.5 mol / L base liquid I, 0.5-2 mmol / L base liquid II, 0.01-0.1% polysorbate 80, 5-20% sucrose and 1-5% trypsin; and the B liquid comprises the following components with terminal concentrations: 0.1-5% trehalose, 0.1-5% oligogalactose and 0.1-2% PEG6000. Through the compounding of the A liquid and the B liquid, the application can effectively enhance the immunization effect of the vaccine, prolong the storage time of the vaccine and keep the virus-like particle form intact.

The invention discloses an interface regulation and control wetting oil displacement agent for improving the recovery ratio of a low-permeability oil field, and the interface regulation and control wetting oil displacement agent comprises the following components in parts by weight: 6-10 parts of dimethylol lauryl sodium sulfate, 2-5 parts of polysorbate-80, 2-4 parts of nanoscale titanium dioxide, 1-2 parts of ethanol and 100-120 parts of deionized water. The interface regulation and control wetting oil-displacing agent can effectively enhance the adsorption effect of the oil-displacing agent on the rock surface, so that the wetting regulation and control capability is improved, and the recovery efficiency of a low-permeability oil field is remarkably enhanced by changing the wettability of the rock surface and an oil-water interface and optimizing distribution and flowing of fluid in pores.

The invention belongs to the technical field of traditional Chinese medicine navel patches, and particularly relates to a composite medicine carrying navel therapy patch based on a PU film and a preparation method thereof.The composite medicine carrying navel therapy patch comprises an anti-sticking release film, a medicine carrying layer, a medical pressure-sensitive adhesive layer and a PU waterproof protective layer; the traditional Chinese medicine extract is prepared from the following raw materials in parts by weight: 10 to 20 parts of rhizoma zingiberis, 10 to 15 parts of roasted rhizoma atractylodis macrocephalae, 8 to 12 parts of radix codonopsis, 5 to 10 parts of fructus evodiae, 5 to 10 parts of fructus foeniculi, 3 to 8 parts of cortex cinnamomi, 1 to 3 parts of borneol, 8 to 20 parts of polysorbate 80, 0.5 to 2 parts of carbomer 940, 1 to 3 parts of triethanolamine and 0.1 to 0.5 part of EDTA-2Na. By means of the integrated design of slow-release hydrogel drug loading and the multi-layer patch, efficient transdermal absorption and stable release of drugs are achieved, and the bioavailability and application comfort of the composite drug-loading navel therapy patch are improved.

The invention discloses a method for extracting fine iron powder from iron-containing minerals by magnetic separation in the field of mineral processing, which comprises the following steps: firstly, coarsely crushing low-grade iron-containing raw ores, carrying out wet ball milling to obtain ore pulp, adding sodium hexametaphosphate and polysorbate 80, and stirring and dispersing; adjusting the pH value of the ore pulp to 5-6 by using diluted hydrochloric acid or sodium hydroxide, adding a quaternary composite modified material with a specific structure, and stirring to enable the material to be in full contact with the iron minerals; then the ore pulp is pumped into a high-gradient magnetic separator, and rough concentrate enriched with iron minerals is separated out under the specific gradient magnetic field intensity; and finally, stirring and desorbing at a constant temperature through a citric acid buffer solution at a certain temperature, magnetically separating to obtain high-grade fine iron powder, and washing and drying the desorbed modified material to be repeatedly used. According to the method, efficient selective extraction of iron in the low-grade iron-containing minerals is achieved through multi-stage structural design and process parameter optimization of the materials, the grade and the recovery rate of the fine iron powder are remarkably improved, and the modified materials can be recycled and are high in environmental friendliness.

The present invention relates to a bio-based microbial retardant composition and a method of preparation thereof The composition comprises lactic acid (2-20% v / v), glutaraldehyde (0.5-10% v / v), Polysorbate 80 (Tween 80) (1-15% v / v), Melia Azadirachta Seed Oil (Neem oil) (0.05-5.5% v / v), and Methylchloroisothiazolinone (Preservative DB20) (0.01-1% v / v). This composition is designed to maintain an acidic pH of 1.5 to 3.5, ensuring immediate microbial retardation. The lactic acid stabilizes the glutaraldehyde, preventing polymerization, while Polysorbate 80 emulsifies Neem oil to enhance antimicrobial action. The preservative inhibits initial microbial contamination, providing immediate suppression of microbial load. The composition is readily biodegradable, exhibiting over 70% degradation within 28 days and is capable of broad-spectrum antimicrobial activity, effective against gram-negative bacteria, fungi, and algae. The composition shows sustained antimicrobial efficacy across multiple generations without inducing resistance. A method of preparing the composition is also provided, involving a sequence of mixing steps for optimal performance.

The invention provides a coenzyme Q10 lipid nanocrystal which is prepared from the following raw materials in percentage by mass through a hot melt extrusion method: 10%-58% of coenzyme Q10, 9.09%-30% of glyceryl monostearate, 14.28%-20% of polysorbate 80 and 14.28%-45% of a water-soluble carrier, and the total amount of all the raw materials is 100%. The particle size of the coenzyme Q10 lipid nanocrystal ranges from 537.2 nm to 936.5 nm; the solid lipid and the water-soluble carrier are combined to serve as a dispersing agent of the coenzyme Q10, so that the coenzyme Q10 can be dispersed in the combined material in a nanocrystal form, the lipid nanocrystal with high drug loading capacity is obtained, the prepared coenzyme Q10 nanocrystal can be quickly dispersed and dissolved out in water, and the preparation method is simple in preparation condition, short in time, low in cost and suitable for industrial production. The method is suitable for industrial production.

The present invention provides compositions and methods for reducing protein loss during drug delivery caused by protein adsorption onto one or more drug delivery system components. [Solution] In some embodiments, the present disclosure provides a composition for preventing the adsorption of proteins to one or more drug delivery system components, the composition comprising succinate and polysorbate 80. In some embodiments, the composition further comprises a therapeutic protein.

The present application relates to a kind of pharmaceutical compositions for preventing and treating allergic rhinitis symptoms, with glycerin 1%~10%, polysorbate 80 0.1%~2%, sodium edetate 0.01%~1% and pharmaceutically acceptable carrier in composition by weight percentage.The composition of the present application scientifically screens components and proportion, can form long-lasting antibiofilm protective layer on nasal mucosa, regulate the rhinitis caused by nasal mucus secretion abnormality due to environment or disease and the like, and has the advantages of good biocompatibility, fast effect, good stability, long-acting water-locking, long-acting, no side effects and the like.

The invention relates to the field of skin care products and cosmetics, and particularly discloses a donkey oil skin care emulsion as well as a preparation method and application thereof. The donkey oil skin care emulsion is prepared from donkey oil, glycerol, white mineral oil, a herba portulacae extracting solution, a rhizoma polygoni cuspidati extract, sodium carboxymethyl cellulose (CMC-Na), beta-cyclodextrin (beta-CD), a rose flower extracting solution, disodium ethylene diamine tetraacetate (EDTA-2Na), polysorbate-80 (tween-80), potassium sorbate and water. The donkey oil skin care emulsion is high in storage stability, good in oxidation resistance and anti-inflammatory effect and capable of repairing ultraviolet damage.

The application belongs to the field of biological pharmacy, and particularly discloses a preparation method of musk heart-activating dropping pills, which comprises the following steps: preparing a salvia miltiorrhiza clear paste, mixing the salvia miltiorrhiza clear paste, artificial musk, total ginsenosides of ginseng stems and leaves, toad venom, artificial ox gall, bear bile powder and borneol with polyethylene glycol 6000 and polysorbate 80, stirring and uniformly mixing, dropping, centrifuging, screening, drying and coating to prepare the musk heart-activating dropping pills. The application has remarkable clinical curative effect, no side effect, high drug stability, fast dissolution, high efficiency and rapid effect. The application further discloses a preparation device of the musk heart-activating dropping pills, wherein the vertical silica gel cleaning strips, the first silica gel cleaning strips and the second silica gel cleaning strips in the silica gel cleaning net frame and the silica gel cleaning strip component are cross arranged, can be in friction contact with different surfaces of the salvia miltiorrhiza in the cleaning process, and can provide comprehensive and detailed cleaning effect. The design not only increases the cleaning area, but also can effectively remove the small dust and impurities on the surface of the salvia miltiorrhiza, and avoids the dead angle which is easily missed in the traditional cleaning mode.

The invention provides a pharmaceutical formulation containing a particulate porous adsorbent selected from the group of aluminosilicates and their salts, with a neutral or basic pH and a particle size between 50 and 800 μm, onto which a mixture of polyoxyethylene sorbitan monooleate (polysorbate 80) is applied with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC, and D8-THC. This formulation improves the bioavailability and release profile of the cannabinoids.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a streptavidin compound preparation with mucus removing and defoaming functions and a preparation process thereof. The preparation consists of streptavidin, sodium bicarbonate, dimeticone, silicon dioxide, polysorbate 80 and a filler / adhesive. The preparation method comprises the following steps: stirring dimeticone and silicon dioxide at 145-155 DEG C to react for 7-8 hours to form a compound through a step-by-step granulation process, performing wet granulation, mixing active ingredients at low temperature, and finally performing dry granulation and sub-packaging. The method is characterized in that 1) streptavidin and dimeticone synergistically decompose mucin and break bubbles, and double-view interference is synchronously eliminated; the pH value in the stomach is maintained to be 7-10 through sodium bicarbonate, the enzyme activity is guaranteed, step-by-step granulation avoids high-temperature damage to the enzyme structure, and 5-minute rapid disintegration is achieved through the 80-mesh sieve granule control technology. The preoperative process is simplified, the drug synergism is improved, and the preparation is suitable for gastroscopy and other scenes.

The present invention relates to the technical field of nanosilver preparation and discloses a method for preparing nanosilver. The method comprises providing a base liquid containing nanosilver particle seed crystals, a dispersant, a gel material, and a solubilizing agent; adding a silver salt solution and a reducing agent solution to the base liquid in parallel, wherein the silver ions are reduced to elemental silver during the addition process; after the silver salt solution is added, a metal chelating agent is added to the reaction system for a full reaction; after the reaction, a slurry is obtained, and solid nanosilver is extracted from the slurry; the solubilizing agent is selected from at least one of sodium oleate, polysorbate 80, and propylene glycol. This method reduces the difficulty of separating and purifying the obtained nanosilver; and the entire preparation process is simple. The obtained nanosilver has a particle size between 200 and 500 nm and good monodispersity, and has broad application prospects in the field of conductive pastes.

The present invention relates to insulin formulations comprising polysorbate 80. The present invention provides, inter alia, aqueous liquid pharmaceutical formulations comprising insulin or an insulin analogue, ionic zinc, a chelating agent, and polysorbate 80.

Provided are a stable secukinumab injection and a preparation method therefor. The stable secukinumab injection is composed of the following ingredients: 50 mg / ml-300 mg / ml of secukinumab, 5 mmol / L-50 mmol / L of histidine and a histidine hydrochloride, 5 mmol / L-50 mmol / L of methionine, 150 mmol / L-400 mmol / L of a low-sugar alcohol, and 0.01%-0.02 of polysorbate 80, wherein the balance is water for injection, and the pH is 5.0-7.0. Stability tests prove that the quality of the stable secukinumab injection is stable, wherein the stability thereof is superior to that of commercial varieties on the market, and same has various indicators that meet the relevant regulations of the Chinese Pharmacopoeia, and has good application prospects.

The invention relates to the technical field of biological medicine, in particular to centipeda minima extracellular vesicle nose drops and a preparation method and application thereof.The centipeda minima extracellular vesicle nose drops comprise active ingredients, plant extracellular vesicles (Cm-EVs) derived from centipeda minima, the concentration of the plant extracellular vesicles (Cm-EVs) is 1 * 10 < 10 >-5 * 10 < 11 > particles / ml; the key active substances are as follows: the content of the Cm-EVs naturally encapsulated sesquiterpene lactone compound centipederin is more than or equal to 50 micrograms per milliliter (detected by HPLC-MS); the pharmaceutical auxiliary materials comprise 0.05 to 0.2 percent (w / v) of sodium hyaluronate, 0.8 to 1.0 percent (w / v) of NaCl and 0.005 to 0.02 percent (v / v) of polysorbate 80; the method has the beneficial effects that the targeted enrichment capability is realized: mucous membrane adhesion is enhanced through surface pectin protein, and the nasal cavity residence time is prolonged to 6 hours (the free medicine is less than 1 hour); the nano-scale particle size (80-200nm) can efficiently penetrate through the mucous layer, and the nasal mucosa drug concentration reaches 20 times of the plasma concentration (rat pharmacokinetic data); the long-acting slow-release property is as follows: the active ingredients are protected by the lipid bilayer, the cumulative release rate of the centipederin within 72 hours reaches 82%, and the free medicine can be completely released within 24 hours.

This invention provides an improved formulation and administration method of an FcRn inhibitor for use in the treatment of autoimmune diseases. [Solution] An aqueous formulation containing approximately 100-300 mg / mL of an FcRn antagonist, 20-60 mM histidine / histidine HCl, 0-70 mM sucrose, 0-150 mM NaCl, 0-250 mM arginine HCl, 0%-0.05% (w / v) polysorbate 20 or polysorbate 80, and 0-15 mM L-methionine. The aqueous formulation has a pH of 6.0-6.5, and the FcRn antagonist consists of a variant Fc region, which consists of two Fc domains that form a homodimer.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition containing chlorbuconazole and a preparation method of the pharmaceutical composition. The invention provides a pharmaceutical composition containing chlorbuconazole as well as a preparation method and application of the pharmaceutical composition. Specifically, the invention discloses a pharmaceutical composition, the pharmaceutical composition comprises chlorbuconazole or a pharmaceutically acceptable salt thereof, polyethylene glycol 400, sorbitan oleate and polysorbate 80, the chlorbuconazole or the pharmaceutically acceptable salt thereof accounts for 1-10% of the total weight of the pharmaceutical composition, and the moisture content of the pharmaceutical composition is lower than 10%. The pharmaceutical composition disclosed by the invention has good dissolution rate and relatively high stability.